- Report Scope:
- Pipeline Assessment – regional breakdown
- Clinical Trials Assessment – trial breakdown by phase
- Commercial Assessment – leading marketed products, current and future players
- Competitive Landscape Analysis – key market events to 2026
GlobalData’s Biosimilars market report shows that CRC clinical trials have demonstrated high enrolment efficiencies. Due to the high prevalence of CRC, Phase III trials are large, and recruited an average of 680 subjects. Immunotherapy has offered diversity to the landscape with the recent launches of Keytruda and Opdivo in the US, and novel kinase inhibitors such as encorafenib + binimetinib will provide targeted therapies for currently underserved patient populations.
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.